Skip to main content

Advertisement

Table 1 Baseline patient characteristics

From: Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

   Anti-CTLA-4 Anti-PD-1 Combination Fisher’s test
  (n = 37) (n = 27) (n = 11) p value
  No. (%) No. (%) No. (%)
Gender  Female 12 (32) 11 (41) 4 (36) 0.848
   Male 25 (68) 16 (59) 7 (64)  
Age at treatment initiation  Mean (SD) 66.2 (13) 69.9 (14) 59.9 (13) 1
   Median 67.4 71 61.1  
ECOG PS (pretreatment)  0 28 (76) 19 (70) 7 (64) 0.736
   > 1 9 (24) 8 (30) 4 (36)  
LDH (pretreatment)  Normal 31 (91) 19 (70) 9 (82) 0.114
   Elevated 0 (9) 8 (30) 2 (18)  
   Unknown 3 0 0  
Response to treatment  POD 22 (59) 10 (37) 4 (36) 0.01
   SD 10 (27) 5 (19) 1 (9)  
   PR 5 (14) 8 (30) 2 (18)  
   CR 0 2 (7) 4 (36)  
   UNC 0 2 (7) 0  
Toxicity  None 8 (22) 4 (15) 0  
   Mild 20 (54) 15 (55) 4 (36) 0.16
   Severe 9 (24) 8 (30) 7 (64)  
GI toxicity  Mild 9 (23.1) 12 (42.9) 3 (27.3) 0.08
   Severe 6 (15.4) 3 (10.7) 6 (54.5)  
Skin toxicity  Mild 15 (38.5) 17 (60.7) 5 (45.5) 0.43
   Severe 0 1 (3.6) 1 (9.1)  
Endocrine toxicity  Mild 5 (12.8) 11 (39.2) 4 (36.4) 0.71
   Severe 0 1 (3.6) 1 (9.1)  
Required treatment termination  Yes 4 (11) 3 (11) 6 (54) 0.006
   No 33 (89) 24 (89) 5 (46)  
  1. Summary of clinical features from 75 melanoma patients treated with anti-CTLA-4 (n = 37), anti-PD-1 (n = 27), or anti-CTLA-4 and anti-PD-1 (n = 11). LDH lactate dehydrogenase, POD progression of disease, SD stable disease, PR partial response, CR complete response, UNC unclassified. Fisher’s exact test was used to examine the significance of the association between patient characteristics and treatment type. Two anti-CTLA-4 patients were sampled twice (11-311, in 2011 and 2013; 12-071, in 2012 and 2013), and one anti-PD-1 patient was sampled twice (13-185, in 2015 and 2016)